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Abstract
Background: Obstetric haemorrhage, sepsis and pregnancy hypertension account for more than 50% of maternal
deaths worldwide. Early detection and effective management of these conditions relies on vital signs. The Microlife®
CRADLE Vital Sign Alert (VSA) is an easy-to-use, accurate device that measures blood pressure and pulse. It
incorporates a traffic-light early warning system that alerts all levels of healthcare provider to the need for
escalation of care in women with obstetric haemorrhage, sepsis or pregnancy hypertension, thereby aiding early
recognition of haemodynamic instability and preventing maternal mortality and morbidity. The aim of the trial was
to determine whether implementation of the CRADLE intervention (the Microlife® CRADLE VSA device and CRADLE
training package) into routine maternity care in place of existing equipment will reduce a composite outcome of
maternal mortality and morbidity in low- and middle-income country populations.
Methods: The CRADLE-3 trial was a stepped-wedge cluster-randomised controlled trial of the CRADLE intervention
compared to routine maternity care. Each cluster crossed from routine maternity care to the intervention at 2-
monthly intervals over the course of 20 months (April 2016 to November 2017). All women identified as pregnant
or within 6 weeks postpartum, presenting for maternity care in cluster catchment areas were eligible to participate.
Primary outcome data (composite of maternal death, eclampsia and emergency hysterectomy per 10,000 deliveries)
were collected at 10 clusters (Gokak, Belgaum, India; Harare, Zimbabwe; Ndola, Zambia; Lusaka, Zambia; Free Town,
Sierra Leone; Mbale, Uganda; Kampala, Uganda; Cap Haitien, Haiti; South West, Malawi; Addis Ababa, Ethiopia). This
trial was informed by the Medical Research Council guidance for complex interventions. A process evaluation was
undertaken to evaluate implementation in each site and a cost-effectiveness evaluation will be undertaken.
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Discussion: All aspects of this protocol have been evaluated in a feasibility study, with subsequent optimisation of
the intervention. This trial will demonstrate the potential impact of the CRADLE intervention on reducing maternal
mortality and morbidity in low-resource settings. It is anticipated that the relatively low cost of the intervention and
ease of integration into existing health systems will be of significant interest to local, national and international
health policy-makers.
Trial registration: ISCRTN41244132. Registered on 2 February 2016.
Prospective protocol modifications have been recorded and were communicated to the Ethics Committees and
Trials Committees. The adapted Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
Checklist and the SPIRIT Checklist are attached as Additional file 1.
Keywords: Stepped-wedge cluster-randomised controlled trial, Complex intervention, Vital signs, Blood pressure,
Pre-eclampsia, Obstetric sepsis, Obstetric haemorrhage, Eclampsia, Maternal death, Hysterectomy
Background
Approximately 800 women die in pregnancy or child-
birth every day [1]. Obstetric haemorrhage (antepartum
and postpartum), sepsis and hypertension in pregnancy
account for more than 50% of maternal deaths world-
wide, 99% of which occur in low- and middle-income
countries (LMICs) [1]. Early detection and effective
management of these conditions relies on vital sign
monitoring, including pulse and blood pressure [2].
Strategies aiming to improve the detection of haemo-
dynamic instability are vital in recognising women in
need of urgent medical care.
There are simple, cost-effective and established inter-
ventions to save lives for each of these pregnancy-related
conditions, but the barrier to initiating treatment lies in
recognition of maternal haemodynamic compromise and
access to interventions [3, 4]. Accurate blood pressure
measurement is essential for detecting and monitoring
pre-eclampsia, enabling antihypertensive and prophylac-
tic anticonvulsant therapy, appropriate transfer to
higher-care facilities for timed delivery and, thereby, pre-
vention of maternal and perinatal mortality and morbid-
ity; however, the majority of blood pressure devices that
are commercially available either fail validation in preg-
nancy or their accuracy is unknown [5]. In LMICs,
hypertension is frequently under-detected, not only be-
cause of poor availability of working and accurate blood
pressure devices, but also because of inadequate training
[6, 7]. Vital sign measurement is equally critical in the
management of obstetric haemorrhage and sepsis [2].
Postpartum haemorrhage, the leading cause of maternal
mortality in LMICs [1], can cause death within a few
hours, but effective interventions are available and early
recognition facilitating immediate intervention is often
lifesaving [8].
The CRADLE Research Group proposes that the
introduction of the CRADLE Vital Sign Alert (VSA) de-
vice, a vital-sign-measuring device and alert tool, inte-
grated with the CRADLE training package, will aid the
early recognition of haemodynamic instability secondary
to haemorrhage, sepsis and pre-eclampsia in LMICs.
The CRADLE VSA device has been validated as accurate
for use in pregnancy, including in women with pre-
eclampsia [9] and is the first device to be validated as ac-
curate in pregnant women with low blood pressure;
from example, from haemorrhage or sepsis [10]. It has
been designed to be robust and longer lasting for use in
community and health facility environments in LMIC
settings [9, 10]. The device is affordable, easy-to-use
(including for community healthcare providers), reliable
and portable. The CRADLE Group has incorporated a
traffic-light early warning system into the device alerting
users to hypertension and shock.
This protocol describes the stepped-wedge cluster-
randomised controlled trial to assess the implementation
and clinical usefulness of the CRADLE intervention in
LMICs.
Methods
Feasibility phase: November 2015 – March 2016
The trial was preceded by a mixed-methods feasibility
phase. The aim was to explore the acceptability and
feasibility of the CRADLE intervention and its imple-
mentation strategies in three non-trial sites representa-
tive of the 10 main trial clusters (Ramdurg, Belgaum,
India, Bishoftu, Ethiopia, Masvingo, Zimbabwe). Simul-
taneously, the 10 main trial clusters collected primary
outcome data to evaluate the methods of data collection,
and to inform the randomisation programme and the
sample size calculation. Results were used to optimise
the final CRADLE-3 protocol including training mate-
rials and implementation strategy for the main trial.
Definitive stepped-wedge cluster-randomised controlled
trial: April 2016 – November 2017
Aim
The primary aim of the trial was to determine whether
implementation of the CRADLE intervention to
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community and facility maternity care reduces a com-
posite of (all-cause) maternal mortality or major morbid-
ity by ≥ 25%.
The trial is complemented by simultaneous process
evaluation informed by the Medical Research Council
(MRC) guidance. The aim of the process evaluation is:
(1) to explore if the CRADLE trial was delivered as
intended (fidelity, dose and adaptation); (2) to under-
stand whether, how and why the intervention had an im-
pact, through exploring healthcare provider (HCP)
perspectives of their usual care and of the intervention
and (3) to explore if the results are likely to be scalable
and sustainable. This will include an evaluation of cost-
effectiveness.
Design and study setting
The CRADLE-3 trial was a pragmatic, mixed-methods,
multicentre, stepped-wedge cluster-randomised con-
trolled trial of the introduction of the CRADLE inter-
vention (CRADLE VSA device and CRADLE training
package) to routine maternity care settings in LMICs. It
was informed by the MRC guidance for evaluation of
complex interventions [11].
Ten clusters were identified to take part in the trial.
Each cluster comprised a secondary or tertiary health
facility with multiple satellite primary care centres that
referred to the central hospital:
1. Gokak, Belgaum, India
2. Harare, Zimbabwe
3. Ndola, Zambia
4. Lusaka, Zambia
5. Free Town, Sierra Leone
6. Mbale, Uganda
7. Kampala, Uganda
8. Cap Haitien, Haiti
9. South West, Malawi
10. Addis Ababa, Ethiopia
Each randomisation cluster crossed over from control
to the CRADLE intervention at 2-monthly intervals
(Figs. 1 and 2 and Additional file 1). At the time each
cluster was randomised to receive the CRADLE inter-
vention, all levels of healthcare providers within that
cluster, involved in the care of pregnant/postpartum
women, had access to the CRADLE intervention. The
intervention effect will be determined by comparing data
points in the intervention section of the wedge with
those in the controlled section.
Participants
Inclusion criteria Women identified as pregnant or
within the 6-week postpartum period, presenting for
antenatal, intrapartum or postpartum care in cluster
catchment areas* within the trial time frame.
*Catchment areas were defined in collaboration with
local principal investigators, and included the major out-
reach facilities that result in women being assessed and
referred to a defined central facility/ies. These were de-
fined prior to randomisation and remained constant
throughout the study period.
There were no exclusion criteria.
Intervention
The CRADLE intervention consisted of two components
and is described according to the TIDieR Checklist [12].
Microlife® CRADLE Vital Sign Alert (VSA) device
The Microlife® CRADLE VSA is a hand-held, upper-arm,
semi-automated device that measures blood pressure
and pulse. The device has undergone extensive testing
for accuracy and is one of few blood pressure devices to
have been validated as accurate in pregnancy, including
in pre-eclampsia and hypotension [10], as well as non-
pregnant adults [13].
The device incorporates a traffic-light early warning
system that alerts all levels of HCP to abnormalities in
blood pressure and pulse secondary to obstetric haemor-
rhage, sepsis and pregnancy hypertension. The thresh-
olds that trigger the traffic lights were determined
through prediction studies [14, 15]. The traffic light early
Fig. 1 Stepped-wedge cluster-randomised controlled trial design. A
schematic representation of the trial design
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warning system triggers are shown in Fig. 3. A ‘red light’
and ‘up arrow’ displayed following vital signs measure-
ment of a pregnant/postpartum woman indicate severe
hypertension and should prompt intervention and/or re-
ferral. Likewise, a ‘red light’ and ‘down arrow’ with
haemorrhage or sepsis should prompt immediate action.
A ‘yellow light’ and either ‘down arrow’ or ‘up arrow’ in-
dicate less urgent need for assessment, intervention and/
or referral. It is proposed that the traffic lights will alert
users to abnormal vital signs, including those without
formal healthcare training. This should enable earlier
management to improve outcomes that would directly
benefit the woman and her unborn/newborn child.
The production costs are less than US$20 per unit and
has been designed to be simple to use, even by unskilled
personnel after minimal training. The device fulfils the
World Health Organisation requirements for automated
devices used in low-resource settings [13]. Other devel-
opments suited to LMICs include a micro-USB charging
ability. The CRADLE VSA is manufactured in Taiwan.
As part of the CRADLE-3 trial intervention, the CRA-
DLE VSA was incorporated into routine maternity care.
Primary, secondary and tertiary facilities were allocated
devices according to their delivery rate, staffing numbers
and number of beds per ward. Pre-existing blood pres-
sure measurement devices were removed from clinical
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
Fig. 3 Vital Signs Alert (VSA) device traffic-light early warning system display options. Legend: SBP systolic blood pressure; DBP diastolic blood
pressure; SI Shock Index
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areas unless existing equipment had functionality de-
signed for that area, e.g. repeated automated measures
in an operating theatre or a high dependency area, and
this was left to the discretion of the lead clinician.
CRADLE training package
The intervention users included every cadre of health-
care professional involved in maternity care within the
cluster. This included community healthcare providers
(cHCPs) where they were supported at district level and
involved in provision of routine maternity care. The
CRADLE research group created a simple CRADLE
training package for prospective CRADLE VSA users.
The training package consisted of short animated
films, an interactive session, action prompt cards at-
tached to the CRADLE VSA and posters. There were
two sets of training materials available, one for facility
HCP (fHCPs) and one for cHCP with very limited re-
sources or no formal training. All materials were trans-
lated into local language where required.
The CRADLE package content covered:
 How to use the CRADLE VSA
 Maintenance of the CRADLE VSA
 Basic overview of clinical assessment and
management of pre-eclampsia/eclampsia and shock
in relation to the traffic-light alerts
At the randomised time point the local implementa-
tion team (clinical research officers responsible for
ongoing CRADLE outcome data collection and site prin-
cipal investigators) attended face-to-face one-off training
with the research team lasting approximately 5 h. The
implementation team and research team subsequently
delivered one-off group training sessions lasting 2–4 h
to local stakeholders and representative HCP from each
of the clinical areas in the cluster.
Attendees were given training materials and CRADLE
VSA to disseminate to their clinical areas. The imple-
mentation team continued to visit clinical areas regularly
to collect outcome data therefore providing ongoing
support to HCP.
The core components of the intervention (the CRA-
DLE VSA, animated films, posters and content of the
training presentation) were standardised across all clus-
ters. Delivery of the core components could be adapted
to meet the needs of the cluster.
Control
This intervention was compared to routine maternity
care. This involved blood pressure monitoring with a
variety of blood pressure devices that were available lo-
cally and management according to local guidelines.
Primary outcome
The rate of a composite of maternal mortality or major
morbidity (one of maternal death, eclampsia or emer-
gency hysterectomy with no double counting per 10,000
deliveries in each cluster each month). We will report
the effect of the intervention on the primary endpoint,
on each of the three components, and on each of the
secondary endpoints.
Maternal death was defined as death during preg-
nancy or within 42 days of delivery (or last contact day if
contact not maintained to 42 days).
Eclampsia was defined as occurrence of generalised
convulsions with increased blood pressure during preg-
nancy, labour or within 42 days of delivery in the ab-
sence of epilepsy or another condition predisposing to
convulsions.
Emergency hysterectomy was defined as surgical re-
moval of all or part of the uterus.
Secondary outcomes
Maternal deaths from all causes were collected with add-
itional information regarding the cause of maternal
death collected to determine the potential for impact of
the CRADLE VSA. The percentage of deaths that oc-
curred as a result of obstetric haemorrhage, pregnancy-
related sepsis and hypertensive disorders of pregnancy
will be presented across all clusters pre and postinter-
vention with adjusted risk ratios (RRs). If there are other
large groups of other clinically important causes of
death, e.g. early pregnancy complications, these will also
be defined.
Maternal secondary outcome measures:
1. Intensive care unit admission, defined as any
admission to a specific intensive care unit or an
equivalent highest-level care environment within
the trial area (or referral to the highest level care fa-
cility outside of the area) in areas where an inten-
sive care unit does not exist
2. Stroke, defined as hemiparesis and/or blindness
developed during pregnancy or in the 42 days
postpartum lasting longer than 48 h
3. Cause of intensive care admission
4. Cause of maternal death
5. Cause of emergency hysterectomy
6. Place of eclamptic fit
7. Place of maternal death
Perinatal secondary outcomes Number of stillbirths
per 10,000 deliveries per month.
Number of neonatal deaths per 10,000 deliveries per
month.
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Process evaluation outcomes The implementation and
impact of the intervention in each site was evaluated by
both quantitative and qualitative measures. The fidelity,
dose, reach and adaptation (whether the intervention is
implemented as planned, to the intended population and
what amount) was determined by measuring:
 The duration and content of training and whether it
was adapted in different contexts (structured
observation of training)
 The proportion of HCPs working in maternity
services that were trained to use the CRADLE device
 The proportion of facilities with access to working
blood pressure devices prior to and after
implementation
 The number of CRADLE VSA delivered
 The proportion of women attending maternity
services that had their blood pressure measured
(subset of clusters for a 4-week period immediately
prior to implementation and the same duration 3
months after implementation)
The potential impact of the intervention, the accept-
ability and potential mechanisms of action were
explored through the following methods:
 Semi-structured interviews of a purposive sample of
HCPs (n = 3–5 in each cluster) at 3 months
following implementation explored the experience of
triage, intervention, referral and transportation and
reception at the higher-level facility, as well as infor-
mation on the escalation process and barriers to
women attending higher-level care
 A focus group discussion with a purposive sample of
stakeholders (n = 5–8 in each cluster) at 3 months
elicited how the CRADLE VSA influences the
process of referrals and work load
 Given our hypothesis that earlier detection will result
in earlier referral and management of pregnancy
complications, an evaluation of the proportion of
women accessing maternity services that were
referred to higher-level care was undertaken (for a 4-
week period immediately prior to implementation and
the same duration 3 months after implementation
The following outcomes were evaluated to explore the
potential for the results to be scalable and sustainable:
 The number of CRADLE VSA reported as broken,
lost or stolen (evaluated monthly after
implementation to trial end; up to 18 months in the
first cluster)
 The proportion of clinical areas using the CRADLE
VSA post implementation (longitudinally assessed
according to time of implementation up to 6, 12 and
18 months)
 Costs of implementation (including equipment, staff,
meeting and training, transport)
 A focus group discussion with a purposive sample of
stakeholders (n = 5–8 in each cluster) at 6 to 9
months and interviews with the implementation
team at 12 months to elicit contextual change over
time and sustainability of the intervention
Quantitative process data will be integrated into the
outcome datasets to examine whether the effects of the
CRADLE intervention differ by implementation. Quali-
tative methods will capture emerging changes in imple-
mentation, experiences of the intervention and
unanticipated or complex causal pathways in addition to
generating new theory about potential mechanisms of
action. Quantitative and qualitative analyses will build
upon one another, with qualitative data used to explain
quantitative findings, and quantitative data used to test
hypotheses generated by qualitative data.
The cost consequence analysis will be modelled on the
basis of the equipment required and the health out-
comes influenced as recorded in the trial. The incremen-
tal financial and economic cost of implementing the
CRADLE intervention (device and training package)
over the trial will be quantified, thereby evaluating the
financial sustainability of the interventions. Research
costs will be excluded from the costs of the intervention.
Cluster description
Each cluster was described according to the number of
primary, secondary and tertiary facilities and their refer-
ral distances. Details on staffing levels and availability of
key resources, such as intensive care beds, blood transfu-
sion and magnesium sulphate use, was collated. In
addition, major changes to the trial catchment, such as
changes to infrastructure, policy, patient payment re-
quirements or environmental conditions, were systemat-
ically reviewed each month.
Data collection
Methods of data collection were discussed and opti-
mised based on the existing resources available in each
site. Outcomes were triangulated across multiple sources
(including referral registers, ward registers, patient re-
cords, local mortality and morbidity records and active
case finding) to ensure data completeness and all out-
comes checked to avoid double counting.
Outcome data were recorded over the 20-month
period. Consistency and quality of source data was mon-
itored by the research midwife/assistant at each cluster
(monthly). Data were entered onto an online database
(MedSciNet). This allows for extensive monitoring and
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query processing features, as well as a comprehensive
alerting system to identify missing data. The trial coord-
inator will monitor data entry continuously on MedSci-
Net. Ten percent of the source data were validated by
the primary investigator and a proportion of this was
reviewed by the trial coordinator. Patient records are
identified with a unique identification number generated
sequentially and no identifying data are stored.
Method of randomisation
The unit of randomisation is the cluster (or clusters), ra-
ther than individual women. Large variation in the pri-
mary event rate was anticipated between clusters;
therefore, a restricted method of randomisation was
used with zero rank correlation between events per
month and order of randomisation. The sequence of
timing for receiving the CRADLE intervention was de-
termined by computer-generated random numbers by
the CRADLE statistician. The clusters were masked to
the order of implementation until they are informed of
their allocation 2 months prior to their implementation
date (to enable training to be arranged).
Sample size calculation
Sample size estimation has been carried out by the CRA-
DLE statistician, using Stata version 13.1 and the
methods of Hemming and Girling [16]. This was in-
formed by data from the feasibility phase. For the pur-
pose of the power calculation an assumption that there
are at least 4000 deliveries per centre per month was
made (or 8000 per cluster period of 2 months) and at
least nine clusters, each observed for 20 months (10
time periods of 2 months each). We anticipated a base-
line event rate of 1% and anticipate a 25% reduction in
this to 0.75% post intervention. We would require a total
of 6300 outcome events, with a coefficient of variation
of 0.4 and an Intra Cluster Correlation of 0.0085, to have
power of 99%. We would require a total of 2450 out-
come events with a coefficient of variation of 0.4, to have
power of 95%.
Statistical plan
The effect of the intervention on the primary outcome,
on each of the three components, and on the secondary
outcomes specified above, will be reported. Results will
be reported firstly as odds ratios (ORs), with risk ratios
(RRs) as a secondary comparison if the appropriate
models converge. Within the stepped-wedge cluster de-
sign it remains appropriate to analyse outcome data
from clusters individually, despite randomising cluster
time points with some clusters paired [17].
The main statistical analysis method will be by logistic
regression, using generalised estimating equations with a
population-averaged model [18] (Stata command xtgee)
with fixed centre effects and separate fixed linear trends
in each centre for changes in outcome over time. Auto-
regressive correlation will account for decreasing corre-
lations between observations over time. This model
outperformed the multilevel model structure of Hussey
and Hughes [19], being apparently less susceptible to
bias. It gives equal weight to each woman, rather than
each centre, and (being population-averaged) reports ef-
fects averaged over the length of the trial. Simulations
studies suggest that using time categories, rather than
linear trends do not correct well for separate time trends
by centre, and can cause convergence problems. Results
will be expressed as ORs; at the low event rates expected
(≤ 5%), ORs and RRs are reasonably close (in the sim-
plest case, for 5% and 3.75%, RR = 0.75, OR = 0.74). A
secondary analysis to obtain RRs using a log link will be
attempted, but simulation studies suggest that the con-
vergence may be poor. We will adjust for centre effects
and linear time trends and the interaction between
them. This will effectively adjust for differences in base-
line availability of resources between clusters.
Discussion
We have described the protocol for a mixed-methods,
multicentre, stepped-wedge cluster-randomised con-
trolled trial. The main objective of this trial is to deter-
mine whether the introduction of the CRADLE
intervention (CRADLE VSA device and CRADLE train-
ing package) to maternity care settings in LMIC com-
munities and facilities reduces maternal mortality and
morbidity. A stepped-wedge cluster-randomised con-
trolled trial design has been chosen to evaluate the inter-
vention in a pragmatic fashion. Individual randomisation
would be logistically difficult and would not measure
impact and transferability at a population level. The
stepped-wedge design is useful where phased implemen-
tation is preferable because of logistical and practical
constraints.
The CRADLE intervention is intended to be beneficial
to all types of practice in a wide variety of settings. In
keeping with the pragmatic trial design, and to ensure
that results are generalisable, efforts were made to en-
sure that participating clusters represented diverse set-
tings, at both a country level with different healthcare
systems and at a facility level. Our study clusters, there-
fore, included academic/specialist facilities, private facil-
ities and primary and secondary-level government
facilities. We hypothesise that the intervention will work
by facilitating earlier detection, referral and treatment of
pregnancy complications.
A composite of maternal mortality or morbidity (one
of maternal death, eclampsia or emergency hysterectomy
with no double counting) was chosen as the primary
outcome as powering a trial for maternal death alone
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would require a prohibitively large sample size. These
are robust and meaningful clinical endpoints that are
unambiguous and, therefore, feasible to collect in these
environments. Maternal complications were selected,
each of which is associated with significant acute and
chronic morbidity. Therefore, a reduction in this com-
posite would be highly desirable. Each component of the
primary outcome will be individually interrogated to en-
sure no paradoxical effects within the composite, i.e. an
increase in morbidity may be associated with a reduction
in mortality, as a consequence of intervention. There-
fore, should the CRADLE intervention result in appro-
priate referral and intervention (e.g. hysterectomy) this
will be recognised as beneficial even though the overall
effect on the composite outcome may be neutral. We
have ensured that all primary outcome measures are
feasible to collect at primary to tertiary facilities, as de-
termined through the feasibility study. It is, therefore,
not necessary to conduct costly household surveys. In
the unlikely event that a primary outcome occurs with-
out HCP contact, this is likely to be unchanged pre and
post intervention and should not affect our ability to as-
sess the impact of intervention implementation.
It is recognised that the CRADLE intervention may re-
duce perinatal mortality and morbidity. Perinatal out-
comes have not been included as primary outcomes as
the intervention is designed specifically to identify ma-
ternal health complications. Many of these occur post-
partum and will not directly influence perinatal
outcomes. Acquisition of detailed perinatal data within
LMIC settings would be a substantial additional cost.
However, the secondary perinatal outcomes will be col-
lected in women who experience a primary outcome.
The potential for this trial to demonstrate reductions in
maternal mortality and morbidity and a positive impact
on the working lives of HCPs will be of interest to local,
national and international health-policy makers. The
CRADLE VSA could become a key tool in achieving the
post-2015 global maternal health goals, as well as facilitat-
ing a basic recommended standard of care, i.e. accurate
blood pressure determination in all pregnant women.
Given the low cost, reliability and accuracy of the device,
if the trial is successful, a low regulatory hurdle and rapid
progression to adoption is anticipated. The trial results
will be generalisable beyond the immediate research set-
ting, as the trial will be carried out in a variety of countries
and at both at community and facility levels. A robust
scale-up strategy will be required to support international
scale-up to allow widespread and equitable access to the
innovation. This will require appropriate resourcing to in-
clude commercial expertise and facilitate partnership be-
tween inventors, manufacturers and governments to
maximise effective and efficient marketing, supply and
distribution through appropriate channels and fair pricing.
Trial status
Ongoing
Additional file
Additional file 1: SPIRIT Checklist. (DOC 122 kb)
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This trial is funded by Medical Research Council (UK), Department for
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through the Department for International Development (UK) Global Research
Programme: addressing the health needs of women and children in the
most disadvantaged populations globally (MR/N006240/1). Neither funding
body, nor Microlife®, had any role in the design of the study or collection,
analysis and interpretation of data or in writing the manuscripts.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
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Ethics approval and consent to participate
Investigators will ensure that this study is conducted in accordance with the
current principles of the Declaration of Helsinki (October 2008). The conduct
of this study will be in full compliance with the relevant regulations and
principles of Good Clinical Practice and equivalent guidance from our trial
countries. Ethical approval has been granted by the Biomedical Sciences,
Dentistry, Medicine and Natural and Mathematical Sciences Research Ethics
Subcommittee at King’s College London (LRS-14/15-1484). Local ethical
approval from each cluster has been granted:
 Ethiopian Public Health Institute, Ethiopia: EPHI6.4/185
 K.L.E Society’s Jawaharlal Nehru Medical College, Belgaum, India:
MDC/IECHSR/2015-16/A-59
 National Health Sciences Research Committee at Zomba Central
Hospital Malawi: NHSRC 15/11/1504
 Office of the Sierra Leone Ethics and Scientific Review Committee
Directorate of Training and Research, Connaught Hospital; Sierra Leone
 Uganda National Council for Science and Technology; Uganda: HS1953
 ERES Converge; Zambia: 20215-Aug-008
 Medical Research Council of Zimbabwe; Zimbabwe: MRCZ/A/1999
 Haiti does not have a formal ethical review process. Memorandums
of understanding were drawn up with each hospital trust and a letter
of support gained from the Ministry of Health
In accord with recognised procedures for stepped-wedge trials [20–22],
primary outcome data will be collected centrally rather than individually.
Institutional-level consent is appropriate considering the following:
 The CRADLE intervention (i.e. vital sign measurement) will be part
of standard care, is of minimal risk, and does not adversely affect the
rights and welfare of the individual women
 The intervention is delivered at the level of the cluster, rather than
the level of the individual woman. The unit of randomisation is the
cluster, not the individual woman and, therefore, standard care will
encompass exposure to the intervention [20]
 The requirement to seek consent from all pregnant/postpartum
women within each trial catchment area may make the trial
unfeasible, particularly considering that the individual woman will be
unidentifiable by the research midwife/assistant at the point of
centralised data collection
Institutional-level consent will be sought to adopt the CRADLE intervention
at the start of the trial (time point zero), prior to implementation of the
intervention at subsequent time points.
Informed written consent will be sought from HCP participating in
interviews, focus group discussions and the evaluation of appropriateness of
referrals log.
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